2001
DOI: 10.2337/diabetes.50.2.436
|View full text |Cite
|
Sign up to set email alerts
|

Redistribution of Sudomotor Responses Is an Early Sign of Sympathetic Dysfunction in Type 1 Diabetes

Abstract: Patients with diabetic neuropathy typically have decreased sweating in the feet but excessive sweating in the upper body. Previous studies of sudomotor function in diabetes have included patients with longstanding disease. The present study was designed to test for the early presence of sudomotor dysfunction and to characterize its relation to glycemic control and other aspects of peripheral nerve function. A total of 37 patients (10 males, 27 females) enrolled in a longitudinal study, in which autonomic funct… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
49
1
7

Year Published

2001
2001
2019
2019

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 70 publications
(59 citation statements)
references
References 31 publications
2
49
1
7
Order By: Relevance
“…Impairments in the SR to local and/or central stimuli has already been reported in other diseases affecting the neural tissues, such as diabetes 11,12,16 , tuberous sclerosis 17,18 , multiple sclerosis The present results showed reduction of 35% to 65% in sweat secretion (induced by PILO and HEAT protocols) among NF1 volunteers compared to non-NF1 individuals. In the PILO tests, the reduction was associated with a decrease in sweating production (SGO = -39%) shown by NF1 males, and with a decrease in both SGO (-47%) and number of active sweat glands (ASG = -34%) presented by NF1 females.…”
Section: Discussionsupporting
confidence: 60%
See 1 more Smart Citation
“…Impairments in the SR to local and/or central stimuli has already been reported in other diseases affecting the neural tissues, such as diabetes 11,12,16 , tuberous sclerosis 17,18 , multiple sclerosis The present results showed reduction of 35% to 65% in sweat secretion (induced by PILO and HEAT protocols) among NF1 volunteers compared to non-NF1 individuals. In the PILO tests, the reduction was associated with a decrease in sweating production (SGO = -39%) shown by NF1 males, and with a decrease in both SGO (-47%) and number of active sweat glands (ASG = -34%) presented by NF1 females.…”
Section: Discussionsupporting
confidence: 60%
“…As a result, most multiple sclerosis patients experience transient and temporary worsening of clinical signs and neurological symptoms during exposure to higher environmental temperatures and exercise 10 . Additionally, exercise intolerance and sweating dysfunction are considered common manifestations of diabetic autonomic neuropathy, even in the early stages of this disease, once the sweating response is diminished or completely suppressed, especially in lower limbs 11,12 . Neuropathy in NF1 patients has been related to nerve compression and/or loss of function by the growth of neurofibromas, or to inappropriate genetic signaling between neural cells, and it is considered to be a benign condition.…”
mentioning
confidence: 99%
“…Hoeldtke et al (13) realizaram um estudo longitudinal com diabéticos comparados com não diabéticos, para caracterizar a presença de disfunção sudorípara como um sinal precoce da disfunção neural periférica e da qualidade do controle habitual do nível glicêmico. Os autores observaram aumento relativo na TS do antebraço e diminuição nos membros inferiores, o que resultava em alteração importante na relação TS braços/pés dos diabéticos que apresentavam controle inadequado da glicemia.…”
Section: Artigo Originalunclassified
“…Signs of sympathetic neuropathy have been described in diabetic patients without parasympathetic neuropathy (24). Indeed, Hoeldtke et al (25) report that sympathetic neuropathy as found from abnormal sudomotor response might be an early complication developing soon after the diagnosis of type 1 diabetes. Our study confirms that sympathetic neuropathy is frequent in type 1 diabetic patients.…”
Section: Follow-up Patientsmentioning
confidence: 99%